Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2014 / Oct / FDA Crackdown on Labs
Regulation and standards

FDA Crackdown on Labs

Plans to regulate laboratory developed tests could stifle innovation

By Roisin McGuigan 10/01/2014 1 min read

Share

0114-202-main.img

The US Food and Drug Administration (FDA) has announced its intentions to regulate laboratory developed tests (LDTs). The agency has had the authority to regulate LDTs since 1976, but until now has refrained from doing so (1). US laboratories have instead been regulated by the Centers for Medicare and Medicaid Services (CMS) using Clinical Laboratory Improvement Amendments (CLIA), which have been in place since 1988.

So why is the FDA stepping in now? It cites the increasing complexity of LDTs, and their roles in critical decision making – in particular relating to personalized medicine. The agency intends to take a “risk-based” approach (similar to the model it currently uses for assessing medical devices); LDTs considered high risk will be brought under the new regulations, while risk tests and tests for rare diseases, which do not have an FDA-approved equivalent, may not require no further guidelines (1).

Although some organizations have come forward to express their support for the new regulations, such as the American Association for Cancer Research, others aren’t so pleased by the proposed changes. The American Medical Association (AMA), the American Clinical Laboratory Association (ACLA), and the Association for Molecular Pathology (AMP) have all met the proposed regulations with some skepticism, pointing to the regulations and accreditation procedures already in place. They also voiced concerns that further regulations could lead to the loss of patient access to required tests, increased cost of testing, and stifled innovation in the laboratory.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. The USA Food and Drug Administration (FDA), “Framework for the Regulatory Oversight of Laboratory Developed Tests (LDTs)”, 31 July 2014. Available at: http://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm407409.pdf.

About the Author(s)

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

More Articles by Roisin McGuigan

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Microbiology and climate change: Building a sustainable future together
Regulation and standards
Microbiology and climate change: Building a sustainable future together

January 27, 2022

1 min read

Playing Chicken With Chicken
Regulation and standards
Playing Chicken With Chicken

October 21, 2016

1 min read

Why is antibiotic resistance in Campylobacter species on the rise – and how can we combat it?

A Pig In a Poke
Regulation and standards
A Pig In a Poke

October 21, 2016

1 min read

When importing livestock for food or breeding, European countries may inadvertently open their borders to superbugs as well

Sneaky Superbugs
Regulation and standards
Sneaky Superbugs

October 21, 2016

1 min read

Norway’s strict LA-MRSA transmission measures prevent the import of almost all live pigs – but the bacteria have found a new way in

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.